Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CrownBio Acquires Rights to Drug Development Models from Shanghai Model Organisms

publication date: Aug 15, 2018

Crown Biosciences, a global CRO, in-licensed rights to translational platforms from Shanghai Model Organisms Center (SMOC). The genetically engineered mouse models include proprietary transgenic and reporter models for oncology, cardiovascular and immunology research. SMOC said the agreement will make its products available globally. In December 2017, CrownBio was acquired by JSR Corporation of Japan for $400 million. The CRO has facilities in China, the US, the UK and Taiwan.

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital